Affiliation: Sanofi-Aventis Deutschland GmbH
- The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki
Sanofi Aventis, CNS Department, 1041 Route 202 206, Bridgewater, NJ 08807, USA
Pharmacol Biochem Behav 98:405-11. 2011..In contrast, the benzodiazepine, diazepam (DZM), produced cognitive impairments. NK2 receptor antagonists like saredutant may therefore yield beneficial effects for mood disorders without the adverse effects of current treatments...
- AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsMark D Black
Sanofi Aventis, Bridgewater, NJ 08807, USA
Psychopharmacology (Berl) 215:149-63. 2011..The psychotomimetic effects of cannabis are believed to be mediated via cannabinoid CB1 receptors. Furthermore, studies have implicated CB1 receptors in the pathophysiology of schizophrenia...
- Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay
Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
Pharmacol Biochem Behav 91:47-58. 2008..o.), respectively. These findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states...